Doctor of Osteopathy Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Jordan Grnak

Internal Medicine Greenville, SC Doctor of Osteopathy

NPI 1922501204 CMS profile 6482940

5 S Lewis Plz, Greenville, SC 29605

Open in the dashboard

General payments

$1,955

98 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Jordan Grnak of Greenville, SC is reported in the CMS Open Payments database as having received $1,955 across 98 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $502 23
2022 General $1,040 54
2021 General $400 20
2019 General $14 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jordan Grnak
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jordan Grnak were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jordan Grnak Internal Medicine median Middle half National median
2019 $14 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $400 $135 $37–$521 $132
2022 $1,040 $141 $42–$496 $149
2023 $502 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Intuity Medical Inc $489 11 payments
  2. GlaxoSmithKline, LLC. $361 19 payments
  3. Novo Nordisk Inc $250 16 payments
  4. Pfizer Inc. $188 11 payments
  5. Dexcom, Inc. $114 8 payments
  6. Amgen Inc. $101 7 payments
  7. Inari Medical, Inc. $69 2 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $67 4 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $57 3 payments
  10. AbbVie, Inc. $54 4 payments
  11. Other $206 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,955 98 payments
Products named General payments · program years 2019–2023
  1. Pogo Automatic Blood Glucose Monitoring System $489 11 payments
  2. TRELEGY ELLIPTA $328 17 payments
  3. RYBELSUS $250 16 payments
  4. Ozempic $233 15 payments
  5. ELIQUIS $145 8 payments
  6. Dexcom G6 Transmitter $114 8 payments
  7. FLOWTRIEVER CATHETER, S $69 2 payments
  8. CT THROMBECTOMY SYSTEM KIT $69 2 payments
  9. Tresiba $69 4 payments
  10. Kerendia $67 4 payments
  11. Other $765 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 119 drugs

Part D claims

5,084

Median for Internal Medicine: 777

Drug cost

$491,133

Median for Internal Medicine: $73,373

Branded share of claims

20.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 111 $135,977
Mounjaro Tirzepatide Brand 62 $74,328
Rybelsus Semaglutide Brand 26 $43,882
Eliquis Apixaban Brand 56 $42,712
Ozempic Semaglutide Brand 33 $36,702
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 31 $22,716
Farxiga Dapagliflozin Propanediol Brand 11 $14,730
Janumet Sitagliptin Phos/Metformin Hcl Brand 14 $13,599
Linzess Linaclotide Brand 11 $12,209
Breo Ellipta Fluticasone/Vilanterol Brand 17 $9,008

The 10 drugs with the highest cost, of 119 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$41,955

Medicare's payments for the services billed

Medicare patients

163

Average age 72

Services billed

548

77 women, 86 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 47%
Diabetes 25%
Ischemic heart disease 21%
Depression 21%
Atrial fibrillation 18%
Chronic kidney disease 18%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

98 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record